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During the last 25 years, clinical autoantibody determinations have changed dramatically.
Old and slow techniques with high diagnostic specificity have been replaced with
automated and faster techniques that most often have a higher diagnostic sensitivity at
the expense of a lower diagnostic specificity. Newer techniques are mostly quantitative,
allowing for follow-up of autoantibody levels. Whereas the older procedures utilized
autoantigens in soluble and native states, most modern techniques rely on autoantigens
attached to surfaces, with the risk of exposure of denatured epitopes. Comparisons
between antibody measurement techniques can be obtained from the results of external
quality assessment programs. As the main objective for external quality assessment is
the monitoring of clinical laboratories, they cannot focus on the kind of low-level and
often polyreactive sera, which are common in the real world and in which a single definite
target response cannot be easily defined. Such common sera are very useful, however,
for analysis of differences between autoantibodymeasurement techniques. The European
Consensus Finding Study Group on Autoantibodies has been working with this approach
for 28 years.
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Introduction
The current era is truly changing the role of autoimmune diagnostics. The interplay between genes
and subsequent environmental exposures leading to autoimmune reactions and ensuing disease has
revealed that traditional diagnoses, such as rheumatoid arthritis (RA), can be subdivided into disease
entities with divergent genetic and environmental triggers and also be characterized by divergent
autoantibody profiles, thus paving the way for larger impact of autoimmunity analyses in diagnostic
settings. Indeed, in the previous 1987 American College of Rheumatology (ACR) RA classification
criteria, rheumatoid factor (RF) was included as the only autoantibody and could account for 25%
(1/4 criteria) of the number of criteria needed to fulfill the classification as RA. In contrast in the
more recent joint European League Against Rheumatism (EULAR)/ACR criteria (1), both RF and
antibodies against citrullinated proteins/peptides (ACPA) are included and can encompass 50% (3/6
points) of the points needed to fulfill the recent RA classification criteria.
Modern autoantibody detection systems, such as enzyme immunoassays (EIA) including enzyme-
linked immunosorbent assay (ELISA), line immunoassay (LIA), and addressable laser bead
immunoassay (ALBIA) with the most common brand name Luminex®, are also mostly more or
less quantitative, whereas older techniques like counter immunoelectrophoresis (CIE) and double
immunodiffusion (DID) are qualitative. These possibilities for autoantibody quantification have
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been utilized in both the new RA (1) and in the tentative new
systemic lupus erythematosus (SLE) criteria (2).
Autoantibody analyses also emerge as prognostic markers
for therapy selection in already diagnosed patients, where, i.e.,
RF/ACPA-positive RA patients have a better response to CD20-
depletion therapy than do seronegative RA patients.
Given the increasing impact of autoantibody analyses in clin-
ical medicine, it is important to pay attention to the recent and
ongoing changes in measurement techniques. There are some
distinct differences between the new and old generations of
autoantibody tests. The old approaches with precipitation and
agglutination techniques detected autoantibody specificities with
high diagnostic specificity (3, 4) and used native antigen in
soluble form, whereas ELISA, LIA, and ALBIA all use antigen
coated to surfaces and thus potentially denatured. This has cre-
ated problems in, e.g., the diagnosis of diabetes mellitus type I-
associated autoantibodies, where for a long time the use of ELISAs
was actively discouraged. More recent ELISA kits have, how-
ever, improved, however, at least sometimes by presenting more
native forms of antigen through the use of capture antibodies or
spacers.
The use of recombinant antigens together with solid phase
techniques has also enabled and/or increased the detection of
non-precipitating autoantibodies such as anti-Ro52 (5).
Another distinction is the diagnostic sensitivity and specificity
of the tests. The newer solid phase-based assays almost universally
present with higher diagnostic sensitivity as compared to CIE or
DID, but at the expense of decreasing diagnostic specificity (6). In
a recent study (7), we compared sensitivity and specificity between
one each of EIA, LIA, and ALBIA for antibodies against double-
stranded DNA (anti-dsDNA) with the traditional Crithidia lucil-
iae immune fluorescent test (CLIFT) comparing an SLE cohort
(n= 178) with a control group consisting of patients with primary
Sjögren’s syndrome or RA, and healthy controls (total n= 249).
CLIFT had the lowest sensitivity and highest specificity, but when
the cutoff for the other techniques was increased to the double
value of the cut-offs recommended by themanufacturer according
to the tentative new SLE criteria (2), they all obtained excellent
specificity, but at the expense of a sensitivity somewhat lower
than for CLIFT. When 11 SLE patients followed consecutively
were evaluated using all fourmethods, ALBIA associated best with
disease activity (7).
A third difference is the use of secondary/detection anti-
bodies. Previously, anti-total immunoglobulin (IgG+ IgA+ IgM)
reagent or polyclonal antibodies raised against total IgG and thus
containing anti-light chain antibodies, which cross-reacted with
other immunoglobulin isotypes, were often used. More modern
test systems almost exclusively use antibodies directed against
the Fcγ chain, thus minimizing cross-reactivity against other
immunoglobulin isotypes.
Another factor to consider is the fact that modern commercial
solid phase assays almost never correct for the background reac-
tivity in individual sera, by, e.g., analyzing sample-specific blank
wells in ELISA. We have, e.g., recently reported that patients with
active visceral Leishmania donovani infection not only react in the
commercial anti-CCP2 test but also react equally strongwith wells
coated with arginine-containing control peptides (8).
Even if percentage specificity differences between different
techniques might seem small, such differences will have a large
impact on the positive predictive value (PPV) of defining a specific
autoantibody in a primary care situation given that SLE and other
systemic rheumatic diseases are very uncommon in unscreened
primary care populations. True comparisons of PPV between dif-
ferent autoantibody techniques are exceedingly rare, however, and
authors often report PPV values based on the relative numbers of
patients and controls investigated in their current study and not
on the actual frequency of the investigated disease in a relevant
real world health care situation.
For a couple of decades, there has been a large number of excel-
lent comparisons performed between differentmodern assays, i.e.,
Ref. (6, 9), but new comparative publications do not keep up with
the pace of introduction of new tests. Importantly, “true” PPV, a
very informative measure, is almost never calculated.
I will discuss some findings of autoantibodies directed against
“extractable nuclear antigens” (ENA) and chose this for two
reasons. First, anti-nuclear antibody (ANA)-associated anti-ENA
reactivities seem, in my view, to be more often afflicted with low-
level reactivities that might influence diagnostic performance as
compared to other disease-specific autoantibodies, such as anti-
tissue transglutaminase in celiac disease, or anti-21-hydroxylase
antibodies in Addison’s disease. Second, in contrast to other
autoantibodies that are ordered individually, multiple anti-ENA
antibodies are usually bundled together in panels with the new
EIA, LIA, or ALBIA techniques, and all results are reported in
parallel to the clinicians. Thus, any decreases in diagnostic speci-
ficity for the individually included anti-ENA autoantibodies will
be additive in the clinical situation.
The examples that I will discuss in the next section are
derived from Swedish and European external quality assessment
programs.
What Information Can We Get from
External Quality Assessment Programs?
During the years 1999–2008, I hosted the Swedish quality assess-
ment program EQUALIS for ANA and anti-ENA in which a total
of 23 laboratories from the Scandinavian countries participated.
Each laboratory obtained blinded samples four times yearly and
reported the analysis results back to EQUALIS. These were there-
after interpreted, and the compiled results were distributed with
comments after each distribution. All users were also invited to
a yearly national meeting for discussions of the findings. The
program still works in essentially the same way.
In 2001, I distributed an IF-ANA negative and anti-SSA/Ro-
positive sample to the participating laboratories. Thirteen labo-
ratories performed full testing for ENA, and the five laborato-
ries using DID or LIA reported the expected response whereas
all eight laboratories using ELISAs for anti-ENA determination
also reported anti-SSB/La. All 13 laboratories reported a negative
IF-ANA.
At that time, some laboratories screened for anti-ENA by doing
IF-ANA, whereas some laboratories performed screening for anti-
ENA ELISA in parallel to the IF-ANA; the latter is currently
the common procedure in Sweden. Our results revealed that the
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IF-ANA screening assay was less sensitive than the follow-up
ELISA for anti-SSB/La antibodies, and that this latter reactivity
would have passed undetected had the sample followed initial
screening using IF-ANA.
Normally, a screening test should be more sensitive than the
ensuing follow-up investigations; a typical situation is the screen-
ing of blood donors for HIV in which the screening test must
detect every single HIV-positive individual at the expense of a
number of false positives that will be ruled out in subsequent con-
firmatory tests. But in the example described above, the situation
was the reverse due to changes in technique, as the sensitivities
of screening test and follow-up tests over time have moved in
opposite directions. The general recommendations for screening
dilution for IF-ANA have moved from a combination of 1/40
(corresponding to 32% of healthy controls positive in the original
publication) and 1/160 (10) to now recommending a screening
dilution corresponding to a specificity of >95% compared to
healthy controls, often equivalent to a 1/160 screening dilution
(11). The techniques employed for anti-ENA follow-up tests have,
conversely inmost laboratories, moved from insensitive precipita-
tion techniques to far more sensitive solid phase-based detection
systems.
The national Swedish QA program is small and only limited
conclusions can be drawn. The United Kingdom National Exter-
nal Quality Assessment Service (UK NEQAS) (12) serves many
European immunology laboratories, and their July 2014 distri-
bution for “Antibodies to nuclear and related antigens” had 732
participants with 635 delivering results (an 87% response rate).
The distribution covers IF-ANA, anti-dsDNA, anti-centromere
responses and anti-ENA treated separately, and I will only focus
on the latter. Compiled results from two distributions are shown
in Table 1. In the upper part, a sample from 2008 is depicted.
There was a considerable consistency among laboratories utilizing
modern techniques (ELISA or ALBIA) that reported the deter-
mination of anti-RNP in the absolute majority of cases, whereas
only one out of very few of the laboratories using precipitation
techniques (DID or CIE) could detect anti-RNP. Moreover, a por-
tion of the laboratories using modern procedures but none of the
laboratories utilizing precipitation techniques also detected anti-
SSA/Ro antibodies. The target response was anti-RNP, implying
that the absolute majority of laboratories with modern techniques
but only a small fraction of laboratories with the original tech-
niques succeeded in their task. In this context, it is worthwhile
to be reminded that the original description mixed connective
tissue disease (MCTD) and its association with the autoantibody
specificity U1snRNP used neither precipitation techniques nor
solid phase immunoassays, but a hemagglutination assay (3).
As is known to everyone working with clinical autoimmunity
diagnostics, patient sera differ tremendously and whereas some
sera exhibit rather high numbers of borderline reactivities, others
are strong and monospecific. An example of the latter is shown
in the bottom of Table 1. In this serum from the July 2011
UK NEQAS distribution, almost every laboratory, irrespective
of technique utilized, detected only the combination of anti-
SSA/Ro and anti-SSB/La without the co-occurrence of any other
autoantibodies.
External quality assessment services need to determine target
responses for all samples, and for that purposemany everyday sera
TABLE 1 | Number of specific anti-ENA responses in two UK NEQAS
samples sorted according to the laboratory techniques employed.
SSA SSB Sm RNP Scl70 Jo-1 Negative
UK NEQAS sample 0821 (target response: anti-RNP)
CIE 0 0 0 0 0 0 4
DID 0 0 0 1 0 0 2
ELISA 42 2 5 272 4 1 6
ALBIA 2 0 0 17 0 0 0
UK NEQAS sample 1142 (target response: anti-SSA/RO+anti-SSB/La)
CIE 7 7 0 0 0 0 0
DID – – – – – – –
ELISA 293 293 1 12 1 2 0
ALBIA 32 32 0 0 0 0 1
Figures represent number of laboratories delivering a certain response.
UK NEQAS, United Kingdom National External Quality Assessment Service; ENA,
extractable nuclear antigens; CIE, counter immunoelectrophoresis; DID, double immune
diffusion; ELISA, enzyme-linked immunosorbent assay; ALBIA, addressable laser bead
immunoassay. No participating laboratories performed DID for the 1142 sample.
TABLE 2 | Number of specific responses for UK NEQAS dispatches for
anti-ENA during 1 year (August 2013–July 2014).
Sample distribution SSA/Ro SSB/La Sm RNP Scl70 Jo-1 Negative
135-1 (August 2013) 296 285 4 3 1 3 0
135-2 (August 2013) 297 40 5 2 0 1 0
136-1 (October 2013) 299 8 2 2 1 1 0
136-2 (October 2013) 5 3 3 3 2 4 94
141-1 (January 2014) 289 9 0 0 0 2 0
141-2 (January 2014) 285 284 0 1 0 3 2
142-1 (March 2014) 12 4 287 277 3 4 3
142-2 (March 2014) 289 172 280 284 2 5 0
143-2 (May 2014) 8 1 0 0 0 0 178
143-2 (May 2014) 296 1 0 0 0 1 1
144-1 (July 2014) 0 0 0 0 269 0 12
144-2 (July 2014) 2 0 17 273 0 0 3
Only responses for ELISA and other similar EIA are included. Two samples are distributed
six times each year. Target responses for the individual distributions are underlined.
UK NEQAS, United Kingdom National External Quality Assessment Service; ENA,
extractable nuclear antigens; EIA, enzyme immunoassay; ELISA, enzyme-linked
immunosorbent assay.
with multiple borderline reactivities are unsuitable. In Table 2,
UK NEQAS anti-ENA responses using ELISAs or other EIAs are
compiled. Except for the expected simultaneous co-determination
of anti-SSB/La in some samples with the target response anti-
SSA/Ro and the occasional co-determination of anti-Sm in one
sample with the target response anti-RNP, very few laboratories
reported positive findings outside the target responses.
In order to fulfill their aims of monitoring the performance
of clinical laboratories, external QA programs thus need to work
with rather straightforward serum samples and rightly do so. But
such sera are not the best for evaluation of subtle differences
between laboratory techniques.
The European Consensus Finding Study
Group on Autoantibodies
Originally initiated as a workshop in 1988 by Walther J van
Venrooij (Nijmegen) and Ravinder N Maini (London), the
European Consensus Finding Study Group on Autoantibod-
ies (ECFSG) is now in its 28th year (13). As described in
the original publication (14) and still valid, the work aims at
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investigating the inter-laboratory agreements concerning autoan-
tibody findings in sera containing unspecified antibodies, and
to gain insight into the variability of autoantibody detection in
routine clinical practice.
Each year in December, ECFSG dispatches 10 blinded sera
to the (currently 43) participating European laboratories. Before
each yearly dispatch, a number of sera have been screened by the
laboratories of the steering board members, and the sera finally
chosen are deliberately selected to discern differences between
laboratories. This means that sera with disagreement in the pre-
screen rounds are often favored. Each participating laboratory
delivers their responses electronically in January, results are com-
piled, and thereafter discussed during a study group session,
which takes place every year in conjunction with the annual
European Workshop for Rheumatology Research (EWRR), and
to which all participating laboratories are invited. The results for
each investigated serum are then discussed in a clinical context. It
is important to note that no commercial interests are involved as
no diagnostic companies or laboratories closely linked to specific
diagnostic companies are allowed to participate in the activities.
The participating laboratories are advised to deliver detailed data
on commercial reagents that have been used, and given the non-
commercial setting the relationship between laboratory data and
use of specific commercial products can be freely discussed dur-
ing the study group sessions. The costs for dispatch of sera and
prescreen meetings have been covered by EULAR grants.
Reference standards defined previously can sometimes be
demonstrated to contain autoantibody specificities undetected at
the time of preparation of the standards. For example, in my own
laboratory in Uppsala, we have detected anti-SSA/Ro52/TRIM21
autoantibodies in the current CDC reference standard for anti-Jo-
1 (15) (unpublished results). Even if such findings do not discredit
the use of the reference standard in anyway, an early detailed char-
acterization of future reference reagents for additive specificities
besides the target specificity is advocated. During recent years,
we have therefore included tentative future or newly launched
reference reagents among the blinded samples in the ECFSG
dispatches, and an anti-dsDNA containing sample evaluated in
2014 will probably be used to manufacture the second WHO
anti-dsDNA reference standard.
Conclusion
The panorama of laboratory techniques used for the determi-
nation of autoantibodies has changed dramatically during the
last decades. Old laboratory techniques for the determination of
autoantibodies (DID, CIE, hemagglutination) are slow and time-
consuming and have higher diagnostic specificity but lower diag-
nostic sensitivity than the modern and faster approaches based
on solid phase-coupled antigens (ELISA, LIA, ALBIA). The older
techniques were mainly based on soluble antigens in native state,
whereas the coupling of the autoantigens to solid phase used
in modern technologies confers the theoretical risk of denatu-
ration of the autoantigens. Modern techniques are often more
quantitative and better for follow-up purposes. New solid phase-
based assays are launched at a high pace. However, the clinical
associations described between specific autoantibodies and spe-
cific disease entities were performed with the previous generation
of autoantibody determination techniques and are not regularly
repeated with new test kits. The PPV of new test systems in the
clinical situation with rare occurrence of systemic autoimmune
diseases is also an issue.
Analysis of results from QA programs can give some insight
into how different autoantibody-containing sera react when ana-
lyzed using different methods. But given their aims of monitor-
ing laboratories, QA programs cannot focus on serum samples
in which results indicate subtle divergences between techniques.
The ECFSG is one body deliberately aiming at investigating con-
troversial sera to understand the differences between different
laboratory techniques in a clinical context, andmore focus on such
efforts are needed.
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